No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
JAZZ Jazz Pharmaceuticals
- 109.290
- -1.020-0.92%
Close May 2 16:00 ET
- 110.000
- +0.710+0.65%
Post 18:28 ET
6.89BMarket Cap22.63P/E (TTM)
113.360High103.010Low1.06MVolume105.140Open110.310Pre Close116.51MTurnover1.73%Turnover Ratio17.92P/E (Static)63.04MShares146.70052wk High1.86P/B6.69BFloat Cap103.01052wk Low--Dividend TTM61.25MShs Float194.730Historical High--Div YieldTTM9.38%Amplitude0.515Historical Low109.732Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
In the preceding three months, 15 analysts have released ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), presenting a wide array of perspectives from bullish to bearish.The table below offers a conden
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $222 Price Target
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $222 price target.
Jazz Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 107.09% Needham → $222 Reiterates Buy → Buy 04/10/2024 67.91% Cantor Fitzgerald → $180 Reiterat
Optimistic Outlook for Jazz Pharmaceuticals Despite Q1 Challenges
Buy Rating Affirmed: Jazz Pharmaceuticals' Resilient Base and Promising Pipeline Drive Positive Outlook
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg